NeurologyLive® Friday 5 — October 18, 2024

Author(s):

Key Takeaways

New myasthenia gravis treatments show promise in reducing corticosteroid use, offering potential therapeutic benefits.
Cladribine capsules are being tested in a phase 3 study for efficacy and safety in generalized myasthenia gravis.
Inebilizumab, an NMOSD therapy, shows promising phase 3 data for myasthenia gravis treatment.
Revised guidelines for restless leg syndrome suggest a shift away from dopamine agonists.
Long COVID discussions emphasize its prevalence, underreporting, and the importance of accurate diagnosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 18, 2024.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]

2: Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]

3: Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]

4: NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

In our latest Q&A for NeuroVoices, the chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the newly updated treatment guidelines for the treatment of restless leg syndrome.

NeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

5: Roundtable Discussion: Unmasking Long COVID Through Understanding Prevalence and Diagnosis

In episode 1 of our latest Roundtable Discussion video series, titled "A Deep Dive: Understanding the Neurological Toll of Long COVID," experts discussed Long COVID prevalence, underreporting, accurate diagnosis, and emphasized that Long COVID serves as an umbrella term.